studies was based on the SWOG-8814 randomized clinical trial, the results of which were published in 2009 and showed that adjuvant treatment including both chemotherapy and tamoxifen yielded a longer survival benefit over tamoxifen alone in hormone
Search Results
The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
Jagar Jasem, Christine M. Fisher, Arya Amini, Elena Shagisultanova, Rachel Rabinovitch, Virginia F. Borges, Anthony Elias, and Peter Kabos
Multigene Testing for Hereditary Cancer: When, Why, and How
Kenneth Offit
advised. An example of a guideline based on risk threshold can be drawn from the Tamoxifen prevention trial that used a 1.67% 5-year risk of developing breast cancer for a 60-year-old woman enrolled in the trial. 6 Population-based mammogram screening
The Science and Practice of Bone Health in Oncology: Managing Bone Loss and Metastasis in Patients With Solid Tumors
Allan Lipton, Robert Uzzo, Robert J. Amato, Georgiana K. Ellis, Behrooz Hakimian, G. David Roodman, and Matthew R. Smith
Mouridsen H Gershanovich M Sun Y . Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group . J Clin Oncol
Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Shrujal Baxi, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Elizabeth Kvale, Robin M. Lally, Terry S. Langbaum, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Deborah A. Freedman-Cass, and Nicole R. McMillian
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Survivorship define menopause as no menses for 1 year in the absence of prior chemotherapy or tamoxifen use, or no menses after surgical removal of all ovarian tissue. Healthy women
Selective Androgen Receptor Modulator in a Patient With Hormone-Positive Metastatic Breast Cancer
Namratha Vontela, Vamsi Koduri, Lee S. Schwartzberg, and Gregory A. Vidal
testosterone and its derivatives with some clinical efficacy. 2 However, androgen therapy fell out of favor due to concerns of aromatization to its virilizing effects, and the availability of tamoxifen and third-generation aromatase inhibitors (AIs). 3
Patients and Clinical Practice Guidelines Development
Rodger J. Winn
.nccn.org . 16 Chlebowski RT Col N Winer EP . American Society of Clinical Oncology Technology Assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition . J Clin Oncol 2002 ; 20
Carcinosarcomas (Malignant Mixed Müllerian Tumor) of the Uterus: Advances in Elucidation of Biologic and Clinical Characteristics
Lauren E. Kernochan and Rochelle L. Garcia
Edited by Kerrin G. Robinson
RE Freedman DM Sherman ME Fraumeni JF Jr . Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer . J Natl Cancer Inst 2004 ; 96 : 70 – 74 . 16 Cotran RS Kumar V Collins T , eds. Robbins Pathologic Basis
Genomics-Based Prognosis and Therapeutic Prediction in Breast Cancer
Stefanie S. Jeffrey, Per Eystein Lønning, and Bruce E. Hillner
; 44 : 671 – 675 . 53 Group EBCTC . Polychemotherapy for early breast cancer: an overview of the randomised trials . Lancet 1998 ; 352 : 930 – 942 . 54 Group EBCTC . Tamoxifen for early breast cancer: An overview of the
Surviving the Perfect Storm: An RVU-Based Model to Evaluate the Continuing Impact of MMA on the Practice of Oncology
David M. Dunning and Thomas A. Paivanas
Dimitrov NV . Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors
Clinical Assessment of Breast Cancer Risk Based on Family History
Kaylene Ready and Banu Arun
; chemoprevention in the form of tamoxifen, which may reduce breast cancer risk by up to 50% 4 , 5 ; prophylactic mastectomy, which reduces breast cancer risk by 90% to 95% 5 – 7 ; and prophylactic oophorectomy, which reduces breast cancer risk by 55% to 70% if
